Home / Companies / Kalceks Riga
Company family
Kalceks Riga: medicine shortages
As of 2 Nov 2026, 11 Kalceks Riga products have a reported shortage across 1 countries, covering 8 medicines.
Products short11rank #175 of 464
Medicines8active ingredients
Countries1/16
New in 90 days0-2 vs market pace
Typical duration10 monthsmedian so far
Manufacturing27%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Ceftriaxone | 2 | 31 Dec 2025 | Commercial decision or withdrawal | 5/16 | |
| Dexmedetomidine | 2 | 31 Dec 2025 | Commercial decision or withdrawal | 4/16 | |
| Metamizole Sodium | 2 | 1 Dec 2026 | Manufacturing problem | 2/16 | |
| Calcium Folinate | 1 | 31 Dec 2025 | Commercial decision or withdrawal | 7/16 | |
| Furosemide | 1 | 22 Sep 2025 | Manufacturing problem | 11/16 | |
| Levosimendan | 1 | 28 Feb 2024 | Commercial decision or withdrawal | 4/16 | |
| Morphine | 1 | 6 May 2026 | Commercial decision or withdrawal | 8/16 | |
| Norepinephrine | 1 | 31 Dec 2025 | Commercial decision or withdrawal | 5/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.